ENLV Enlivex Therapeutics
- 1.380
- -0.060-4.17%
Enlivex Therapeutics News
We're Keeping An Eye On Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn Rate
Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Clever Leaves Holdings Inc. (NASDAQ:CLVR) fell sharply during Monday's session after the company announced that it will voluntarily delist its common shares from the Nasdaq and deregister it
Enlivex Therapeutics: Promising Trial Results for Allocetra
HC Wainwright & Co. Reiterates Buy on Enlivex Therapeutics, Maintains $7 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Enlivex Therapeutics with a Buy and maintains $7 price target.
Enlivex Announces Dosing Of First Two Patients In Its Randomized, Controlled Phase I/II Trial Evaluating Allocetra In Patients With Knee Osteoarthritis
Enlivex Therapeutics Ltd. (NASDAQ:ENLV, the "Company"))))), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the first two patients have been dosed in the Company'
Enlivex Announces Authorization From Danish Medicines Agency For A Randomized, Controlled Phase I/II Trial Evaluating Allocetra In Patients With Knee Osteoarthritis
Enlivex Announces Authorization From Danish Medicines Agency For A Randomized, Controlled Phase I/II Trial Evaluating Allocetra In Patients With Knee Osteoarthritis
Will Enlivex Therapeutics (NASDAQ:ENLV) Spend Its Cash Wisely?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, biotech and mining exploration companies often lose mo
BSGM, ENLV and WISA Among Mid-day Movers
Tesla To $180? Here Are 10 Top Analyst Forecasts For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Citigroup
Enlivex Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Enlivex Therapeutics Is Maintained at Buy by HC Wainwright & Co.
HC Wainwright & Co. Maintains Buy on Enlivex Therapeutics, Lowers Price Target to $7
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Enlivex Therapeutics with a Buy and lowers the price target from $12 to $7.
Enlivex Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/12/2024 280.43% HC Wainwright & Co. $12 → $7 Maintains Buy 09/25/2023 552.17% HC Wainwright & Co. $15 →
Sector Update: Health Care Stocks Softer Late Afternoon
Health care stocks were lower late Thursday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) both easing around 0.3%. The iShares Biotechnology ETF (IBB) ro
Sector Update: Health Care
Health care stocks fell late Thursday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) both easing 0.1%. The iShares Biotechnology ETF (IBB) rose 0.6%. In c
Enlivex Therapeutics Shares Fall After Topline Data From Sepsis Treatment Study
Enlivex Therapeutics (ENLV) shares fell 55% in recent Thursday trading activity after the company released topline data from a phase 2 trial of Allocetra, an off-the-shelf treatment candidate of sepsi
Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Fastenal Company (NASDAQ:FAST) fell sharply during Thursday's session following worse-than-expected first-quarter financial results. Fastenal reported first-quarter FY24 sales growth of 1.9
NKTR, VERU and EGIO Among Mid-day Movers
Dow Dips 100 Points; CarMax Earnings Miss Views
U.S. stocks traded mixed midway through trading, with the Dow Jones index falling around 100 points on Thursday. The Dow traded down 0.35% to 38,328.18 while the NASDAQ rose 0.50% to 16,251.71. The S&
Enlivex Stock Plunges 50% on Mixed Results From Sepsis Study
Enlivex Therapeutics, Nyxoah SA, China SXT Pharmaceuticals Among Healthcare Movers
Analysis
Price Target
No Data
